Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04820179 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Results posted: Sep 11, 2026
    • Secondary endpoints revised (4)
    v19
  2. Enrollment target: 30 to 32
    • Secondary endpoints: details revised at 1 of 4 entries
    v18
  3. Study completion pushed from Jan 31, 2026 to Jan 31, 2027
    • Primary completion date changed from estimate of Jan 31, 2026 to Feb 20, 2026
    v17
  4. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 29 to confirmed 30
    • Site details revised
    v16
  5. Primary and study completion dates: Oct 31, 2025 to Jan 31, 2026v15
Show 13 earlier versionsHide 13 earlier versions
  1. Primary and study completion dates: May 31, 2025 to Oct 31, 2025v14
  2. Primary and study completion dates: Mar 1, 2025 to May 31, 2025
    • Site contact updated
    v13
  3. Eligibility criteria expanded, about 28 words
    • Site contact updated
    v12
  4. Secondary endpoints: 7 to 4
    • Eligibility criteria expanded, about 4 words
    v11
  5. Primary and study completion dates: Mar 1, 2024 to Mar 1, 2025v10
  6. Re-verified, no change to tracked fieldsv9
  7. Eligibility criteria expanded, about 96 wordsv8
  8. Site contact updatedv7
  9. Primary and study completion dates: Mar 1, 2023 to Mar 1, 2024v6
  10. Site contact updatedv5
  11. Re-verified, no change to tracked fieldsv4
  12. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Primary completion date: May 1, 2022 to Mar 1, 2023
    • Study completion date: May 1, 2023 to Mar 1, 2023
    • Start date changed from estimate of Aug 1, 2021 to Oct 12, 2021
    • Site details revised
  13. Start date: May 1, 2021 to Aug 1, 2021v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pancreatic cancer is one of the leading causes of cancer deaths in the United States with limited treatment options, especially for those patients with metastatic disease. Combination treatment with cabozantinib and atezolizumab, has demonstrated safety for the treatment of other cancers and has shown promise in preclinical studies utilizing patient derived pancreas organoids. In this study, patients with refractory, metastatic pancreatic cancer will receive combination cabozantinib + atezolizumab and the efficacy of this treatment will be assessed through overall response rate (ORR), disease control rate (DCR), median overall survival (mOS), and median progression free survival (mPFS). Safety and tolerability of combination cabozantinib plus atezolizumab in metastatic pancreatic cancer patients will also be assessed and immune profiling pre- and post-treatment will be explored.
Trial Details
NCT Number NCT04820179
Lead Sponsor University of Arizona
Conditions
(from sponsor)		 Pancreatic Cancer, Metastatic Pancreatic Cancer
Related terms Pancreatic Neoplasms
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov